Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21465758 | 0.84 | MAPK1 (0.40) | MAPK1HRH3NFKB1NFKB2RELA | |
| SCHEMBL1298062 | 0.75 | HRH3 (0.43) | MAPK1HRH3NFKB1NFKB2RELA | |
| SCHEMBL321152 | 0.74 | MAPK1 (0.44) | MAPK1HRH3NFKB1NFKB2RELA | |
| SCHEMBL14169266 | 0.74 | MAPK1 (0.41) | MAPK1HRH3BTKCHRM2CHRM1 | |
| SCHEMBL8772002 | 0.73 | MAPK1 (0.38) | MAPK1HRH3NFKB1NFKB2RELA | |
| SCHEMBL186721 | 0.71 | HRH3 (0.51) | MAPK1HRH3BTKCHRM2CHRM1 | |
| SCHEMBL28492122 | 0.71 | HRH3 (0.51) | MAPK1HRH3BTKCHRM2CHRM1 | |
| SCHEMBL1295721 | 0.71 | HRH3 (0.51) | MAPK1HRH3BTKCHRM2CHRM1 | |
| SCHEMBL11013935 | 0.70 | MAPK1 (0.42) | MAPK1NFKB1NFKB2RELACHRM2 | |
| SCHEMBL17446122 | 0.70 | MAPK1 (0.39) | MAPK1HRH3NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025037229-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | MAPK1, MAP3K1, MAPK6 | MAPK1 1/4885HRH3 2892/4885NFKB1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.